Covalon To Showcase New Wound Healing and Infection Management Products at MEDICA

TORONTO, Nov. 19, 2013 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, will showcase new products at MEDICA the world's largest medical technology trade fair, November 20 to 23 in Düsseldorf, Germany.

Brian Pedlar, Covalon's Chief Executive Officer said, "Since we announced the transformative license agreement with Molnlycke earlier this month, the amount of interest in our new product pipeline has spiked significantly.  As a result, we have accelerated the unveiling of our FDA-cleared ColActive^® Transfer wound dressing and our CovaCoat™ A.I. Anti Infective coatings.  Along with our proven ColActive^® Plus wound dressings and SilverCoat™ Antimicrobial Foley Catheters, our strong pipeline of new products and technologies, which includes ColActive^® Transfer and CovaCoat™ A.I., positions Covalon well as a partner for wound care, urological, vascular access, surgical and orthopaedic companies and distributors."

The latest addition to the patented ColActive™ family of wound care products being showcased at MEDICA is ColActive^® Transfer, Covalon's bio-degradable wound dressing that stimulates wound healing responses in difficult to heal wounds, while allowing wound fluids to pass through the dressing.  ColActive^® Transfer is designed to protect new-growth tissue in wounds undergoing treatment and is FDA approved for sale in the United States.  Along with the introduction of ColActive^® Transfer, Covalon anticipates entering the nearly US$500 million negative pressure dressing and kit market.

Covalon will also be unveiling its new patented CovaCoat™ A.I. Anti Infective coating technology that provides antimicrobial and anti-thrombogenic properties, without eluting antimicrobial agents from the surface of medical devices. Covalon's CovaCoat™ A.I. Anti Infective Foley Catheter significantly reduces biofilm formation on urinary catheters, the formation of which is a major source of hospital acquired infections.  The use of CovaCoat™ A.I. on vascular access devices provides both anti-thrombogenic and antimicrobial characteristics without the downside of delivering potentially cytotoxic antimicrobial agents directly into the bloodstream.

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

SOURCE Covalon Technologies Ltd.